Sitagliptin Phosphate Set to Soar in Sales 
In the United States alone, 90-95 percent of the cases of Diabetes are Type 2, according to the Centers for Disease Control and Prevention. This number translates into one out of every ten adults in the U.S., but predictions from the CDC are ominous. By the year 2050 the CDC estimates that nearly one out of every three adults in the United States could have Type 2 Diabetes, putting the medical and pharmaceutical industry under great demands.
Genetic susceptibility is also being considered by researchers who are studying the development of Type 2 Diabetes in specific populations and groups worldwide. For example, the Israeli Circassians, a small community comprised of both culturally and genetically homogeneous people, has high rates of Type 2 Diabetes. In a study published by the Israeli Medical Association, 450 women and 289 men from the Circassian community participated in a study to determine their risk factors and prevalence for Type 2 Diabetes. Of these participants information was gleaned which showed obese participants with a family history of Type 2 Diabetes had double the chance of getting the disease. Age, BMI, smoking and triglyceride counts factored into the rates, but by far the family history proved to be the most important risk factor for Type 2 Diabetes. With a probable genetic epidemiology for Type 2 Diabetes, as well as the western diet adopted in many countries worldwide, cases of this crippling disease are sure to amass.
Promising data emerged at the 61st Annual Scientific Meeting of the Gerontological Society of America which indicated Januvia (Sitagliptin Phosphate) shined in studies centered around elderly patients. Blood sugar levels in the elderly patient participants with Type 2 Diabetes who received Sitagliptin Phosphate was significantly reduced, and did not lead to hypoglycemia. Merck presented the results of this 24-week randomized and double-blind study at the meeting, which was comprised of 206 patients between 65 to 96 years of age. The concern for the adverse effect of hypoglycemia, which is common in the elderly population taking anti diabetic medications, was quelled. There was not one report of hypoglycemia in the participants, both in the Sitagliptin Phosphate and the placebo groups.
The clinical development of Sitagliptin Phosphate is robust, with Merck estimating that approximately 7,400 patients have been treated with Sitagliptin Phosphate. Of those patients, approximately 2,300 patients have been treated with Sitagliptin Phosphate for more than one year and, of these, approximately 500 patients have been treated for at least two years. These statistics are reassuring for scientists creating future generic formulations of Sitagliptin Phosphate, and also for the future patients who will be seeking treatment for Type 2 Diabetes.
2012 All rights reserved by Yes Pharma Ltd.
Source: http://www.yespharma.com/uploads/files/Sitagliptin_%20CAS_486460-32-6_www.Yespharma.com.pdf
Georg-August-Universität Göttingen, Bereich Humanmedizin Publikationen und Hochschulschriften 2005 Abteilung "Gynäkologie und Geburtshilfe" Journalbeiträge 1. Eicke N, Günthert AR, Viereck V, Siebold D, Béhé M, Becker T, Emons G, Gründker C (2005) GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. EUR J ENDOCRINOL, 153(4
CUSTOM MEDICAL KIT Organization: Number: Email: How many people will use this kit? Trip Duration: Quantity of kits to be ordered: Destination (please check one): _____ Developed Country _____ Developing Country Check here if you want a medical advisor to provide consultation on this order. Please indicate the products and quantities desired. If you do